Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

CoreAge Rx vs Omada Health

CoreAge Rx
Graded #1

Higher grade

vs+36.199999999999996
Omada Health
Graded #436

Lower grade

The verdict

CoreAge Rx takes it — 91.8/100 to 55.6/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

CoreAge Rx is also our overall #1 pick — it tops the full scorecard at 91.8/100 (A−).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCoreAge Rx +47
92
45
Dose & formulationCoreAge Rx +48
88
40
Clinical oversightCoreAge Rx +16
93
77
Labs & monitoringCoreAge Rx +29
90
61
FulfillmentCoreAge Rx +33
95
62
Contract termsCoreAge Rx +41
96
55
CoreAge Rx · left barOmada Health · right bar

The numbers

MetricCoreAge RxOmada Health
WeighScore91.8/10055.6/100
GradeA−C
Scorecard rank#1#436
Semaglutide$149/moNot disclosed
Tirzepatide$349/moNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
CoreAge Rx

Graded #1 · A−

Strengths

  • Flat all-in price with no month-two step-up
  • Semaglutide and tirzepatide on one account
  • All 50 states, LegitScript-verified

Where it loses points

  • Not the cheapest sticker price
  • Compounded only
  • Pharmacy partner not yet publicly named
Omada Health

Graded #436 · C

Strengths

  • Added GLP-1 prescribing and medication management in late 2025
  • Clinicians trained in obesity care, available in all 50 states
  • Behavioral support wrapped before, during and after treatment
  • GLP-1 Flex Care adds a cash-pay medication pathway in 2026
  • Publicly traded, evidence-based virtual care platform

Where it loses points

  • Core program distributed via employers and health plans, limited cash-pay
  • GLP-1 prescribing is a recent addition still scaling
  • GLP-1 Flex Care only rolling out to employers later in 2026
  • No transparent published price for the core member program

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard